SAB Biotherapeutics (SABS) Cash from Operations (2020 - 2026)

SAB Biotherapeutics has reported Cash from Operations for 7 years, with the latest figure at 14271130.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 83.03% year-over-year to 14271130.0; the trailing twelve-month figure through Mar 2026 stood at 51249024.0 (down 63.53% YoY), and the FY2025 full-year result was 44775111.0, down 30.57% from the prior year.
• Cash from Operations for Q1 2026 stood at 14271130.0, up from 16776327.0 in the prior quarter.
• The five-year high for Cash from Operations was 1555024.0 in Q4 2022, with the low at 16776327.0 in Q4 2025.
• Historically, Cash from Operations has averaged 8348068.59 across 5 years, with a median of 7797217.0 in 2025.
• The largest YoY upside for Cash from Operations was 83.16% in 2023 against a maximum downside of 764.73% in 2023.
• SAB Biotherapeutics' Cash from Operations stood at 1555024.0 in 2022, then plunged by 764.73% to 13446717.0 in 2023, then increased by 29.11% to 9532188.0 in 2024, then slumped by 76.0% to 16776327.0 in 2025, then increased by 14.93% to 14271130.0 in 2026.
• The last three Cash from Operations figures came in at 14271130.0 (Q1 2026), 16776327.0 (Q4 2025), and 13050023.0 (Q3 2025), per Business Quant data.